Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-04-26
2011-04-26
Harris, Alana M. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007100, C435S007210, C435S007920, C436S063000, C436S064000, C436S164000, C436S166000, C436S172000, C436S174000, C436S501000, C530S350000, C530S386000, C530S387100, C530S387300, C530S388200
Reexamination Certificate
active
07932047
ABSTRACT:
The present invention relates to a method for the early diagnosis of neoplastic disorders such as cancers as well as their precursor stages, particularly cancers of the respiratory tract, the urinary system, the reproductive tract, cancer associated with HPV infection or cancer of the anogenital tract, from solubilized body samples. The invention is also directed to test kits usable for this purpose as well as in-vitro diagnostic devices. The development of the kits and in-vitro diagnostic devices for the above purpose is also one aspect of the present invention.
REFERENCES:
patent: 4281061 (1981-07-01), Zuk et al.
patent: 5489537 (1996-02-01), Van Aken
patent: 5624819 (1997-04-01), Skolnick et al.
patent: 5739027 (1998-04-01), Kamb
patent: 5801236 (1998-09-01), Kamb
patent: 5889169 (1999-03-01), Beach et al.
patent: 5976799 (1999-11-01), O'Brien et al.
patent: 5989815 (1999-11-01), Skolnick et al.
patent: 5994095 (1999-11-01), Kamb
patent: 6033847 (2000-03-01), Sherr et al.
patent: 6037462 (2000-03-01), Kamb
patent: 6060301 (2000-05-01), Kamb
patent: 6090579 (2000-07-01), Albone et al.
patent: 6140473 (2000-10-01), Kamb
patent: 6180776 (2001-01-01), Kamb
patent: 6210949 (2001-04-01), Stone et al.
patent: 6218146 (2001-04-01), Kamb
patent: 6277579 (2001-08-01), Lazar et al.
patent: 6316208 (2001-11-01), Roberts et al.
patent: 6355424 (2002-03-01), Lorincz et al.
patent: 6403383 (2002-06-01), Casterlin et al.
patent: 6576420 (2003-06-01), Carson et al.
patent: 6686151 (2004-02-01), Lazar et al.
patent: 6709832 (2004-03-01), Von Knebel Doeberitz et al.
patent: 7306926 (2007-12-01), Doeberitz et al.
patent: 7517662 (2009-04-01), Ridder et al.
patent: 2001/0039023 (2001-11-01), Schubert
patent: 2001/0051364 (2001-12-01), Michon et al.
patent: 2002/0086288 (2002-07-01), Bird et al.
patent: 2002/0106685 (2002-08-01), Henning et al.
patent: 2002/0127545 (2002-09-01), Lorincz et al.
patent: 2003/0091992 (2003-05-01), Lorincz et al.
patent: 2003/0157482 (2003-08-01), Keesee et al.
patent: 2003/0175768 (2003-09-01), Carson et al.
patent: 2004/0023288 (2004-02-01), Ridder et al.
patent: 2004/0180362 (2004-09-01), Lazar et al.
patent: 2004/0180388 (2004-09-01), Von Knebel Doeberitz et al.
patent: 2004/0202996 (2004-10-01), Williams et al.
patent: 2005/0084858 (2005-04-01), Wasielewski et al.
patent: 2005/0118568 (2005-06-01), Karlsen
patent: 0643836 (1995-03-01), None
patent: 0723156 (1996-07-01), None
patent: 1038022 (2000-09-01), None
patent: 1038029 (2000-09-01), None
patent: 1217377 (2002-06-01), None
patent: 1230396 (2002-08-01), None
patent: 1305631 (2003-05-01), None
patent: 1333278 (2003-08-01), None
patent: 1388734 (2004-02-01), None
patent: 1463839 (2004-10-01), None
patent: 1470419 (2004-10-01), None
patent: 1525476 (2005-04-01), None
patent: WO 9220796 (1992-11-01), None
patent: WO 93/12426 (1993-06-01), None
patent: WO 9904238 (1999-01-01), None
patent: WO 99/29890 (1999-06-01), None
patent: WO 99/31273 (1999-06-01), None
patent: WO 00/31538 (2000-06-01), None
patent: WO 01/36681 (2001-05-01), None
patent: WO 02/08764 (2002-01-01), None
patent: WO 03/057914 (2003-07-01), None
patent: WO 03/065035 (2003-08-01), None
patent: WO 2004/013632 (2004-02-01), None
patent: WO 2004/092734 (2004-10-01), None
He, et al., “Expression, Deletion and Mutation of p16 Gene in Human Gastric Cancer”World J. of Gastroenterology7(4): 515-521 (2001).
Myung, et al., “Loss of p16 and p27 Is Associated With Progression of Human Gastric Cancer”Cancer Letters153:129-136 (2000).
Nakao et al., “Induction of p16 During Immortalization HPV 16 and 18 and Not During Malignant Transformation”British J of Cancer75(10):1410-1416, 1997.
O'Nions, et al., “p73 Is Over-Expressed in Vulval Cancer Principally As the Δ2 Isoform”British J. Cancer85(10):1551-1556 (Nov. 2001).
Sano, et al., “Overexpression of P16 and P14ARF Is Associated With Human Papillomavirus Infection in Cervical Squamous Cell Carcinoma and Dysplasia”Pathology Int. 52:375-383 (May 2002).
Sano et al., “Expression Status of p16 Protein Is Associated With Human Papillomavirus Oncogenic Potential in Cervical and Genital lesions”American J. Pathology153(6)1741,1998.
Sherr, “The Ink4a/Arf Network in Tumor Suppression”Nature Reviews Mol. Cell Bio2:731-737, (2001).
Takeuchi, et al., “Altered p16/MTSi/CDKN2 and Cycling D1/PRAD-1 Gene Expression Is Associated With the Prognosis of Squamous Cell Carcinoma of the Esophagus”Clinical Cancer Research3:2229-2236, (1997).
Tsujie, et al., “Expression of Tumor Suppressor Gene p16INK4 Products in Primary Gastric Cancer”Oncology58:126-136 (2000).
Castle Philip E et al: “Stability of archived liquid-based cervical cytologic specimens”, Cancer, vol. 99, No. 2, Apr. 25, 2003, p. 89-96, XP002331364.
Klaes R et al: “Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri”, Int. Journal of Cancer, New York, vol. 92, No. 2, 2001, p. 276-284, XP002225497.
Brule Van Den A J C et al: “Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction”, Journal of Clinical Microbiology, Washington DC, vol. 28, No. 12, 1990-12, p. 2739-2743, abstract p. 2739, col. 2, line 5—p. 2741, col. 1, line 4, XP009015539.
Agoff, S. Nicholas, M.D., et al., p16INK4a“Expression Correlates with Degree of Cervical Neoplasia: A Comparison with ki-67 Expression and Detection of High-Risk HPV Types”, The United States and Canadian Academy of Pathology, Inc., vol. 16, No. 7, pp. 665-673 (2003).
Aho et al. (J. Cell Sci. Apr. 1, 2002; 115 (Pt 7): 1391-1402).
Betticher, et al., “Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer”, British J. of Cancer 73: 294-300 (1996).
Bhakdi, Sucharit (J. Biochem. Biophys. Methods. Jan.-Feb. 2, 1980; 2 (1): 79-90).
Bibbo et al. (Acta Cytologica. Jan.-Feb. 2002; 46 (1): 25-29).
Browne, et al., “Analysis of the L1 Gene Product of Human Papillomavirus Type 16 by Expression in a Vaccinia Virus Recombinant”, J. gen. Virol., 69: 1263-73 (1988).
Carayol, et al., “NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions”, Eur. J. Immunol. 28: 1991-2002 (1998).
Castellano et al. Cancer Res. Nov. 1, 1997; 57: 4868-75.
Cattoretti, et al., “Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections”, Journal of Pathology, 168: 357-363 (1992).
Chilton, et al., “Estrogen Regulation of the Central Enzymes Involved in O- and N-Linked Glycoprotein Assembly in the Developing and the Adult Rabbit Endocervix”, Endocrinology, 123(3): 1237-44 (1988).
Dai et al. Gastroenterology. 2000; 119: 929-42.
Davey et al. (Arch. Pathol. Lab. Med. Feb. 2000, vol. 124, pp. 203-211).
Day et al. (Am J Clin Pathol. 2002; 118: 41-46).
De Boer, et al., “Changing Roles of Cadherins and Catenins during Progression of Squamous Intraepithelial Lesions in the Uterine Cervix”, American Journal of Pathology, 155(2): 505-515 (1999).
Di Loreto et al., “Different binding to squamous and columnar epithelium of the uterine cervix as a marker of epithelial differentiation”, Bas. Appl. Histochem. 31: 143-52 (1987).
Dimitriadis, Giorgos J. (Anal. Biochem. Oct. 1, 1979; 98 (2): 445-451).
Epenetos, et al., “Use of Two Epithelium-Specific Monoclonal Antibodies for Diagnosis of Malignancy in Serous Effusions”, The Lancet, 1004-6 (Nov. 6, 1982).
Geradts et al. (Am. J. Pathol. Jun. 1999; 154 (6): 1665-1671).
Geradts, et al., “Immunohistochemical Detection of the Cyclin-dependent Kinase Inhibitor 2/Multiple Tumor Suppressor Gene 1 (CDKN2/MTS1) Product p16INK4A in Archival Human Solid Tumors: Correlation with Ret
Doeberitz Magnus Von Knebel
Duwe Alexander
Herkert Matthias
Hipfel Rainer
Martin Peter
Harris Alana M.
Kung Viola T.
MTM Laboratories AG
Perkins Coie LLP
LandOfFree
Method for detecting neoplastic disorders in a solubilized... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for detecting neoplastic disorders in a solubilized..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for detecting neoplastic disorders in a solubilized... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2734748